Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

被引:9
|
作者
Zeng, Haiyan [1 ]
Zheng, Danyang [2 ,3 ]
Witlox, Willem J. A. [4 ]
Levy, Antonin [5 ,6 ]
Traverso, Alberto [1 ]
Kong, Feng-Ming [2 ,3 ]
Houben, Ruud [1 ]
De Ruysscher, Dirk K. M. [1 ]
Hendriks, Lizza E. L. [7 ]
机构
[1] Maastricht Univ Med Ctr, GROW Sch Oncol, Dept Radiat Oncol Maastro, Maastricht, Netherlands
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China
[3] Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen, Peoples R China
[4] Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
[5] Gustave Roussy, Dept Radiat Oncol, Villejuif, France
[6] Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France
[7] Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, Dept Pulm Dis, Maastricht, Netherlands
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
small cell lung cancer; brain metastasis; risk factors; systematic review; meta-analysis; PROPHYLACTIC CRANIAL IRRADIATION; RANDOMIZED PHASE-II; LIMITED-STAGE; THORACIC RADIOTHERAPY; COMPLETE REMISSION; RADIATION-THERAPY; CLINICAL-TRIAL; CHEMOTHERAPY; SURVIVAL; CHEMORADIOTHERAPY;
D O I
10.3389/fonc.2022.889161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC) patients is controversial. Risk factors for brain metastasis (BM) development are largely lacking, hampering personalized treatment strategies. This study aimed to identify the possible risk factors for BM in SCLC.We systematically searched the Pubmed database (1 January 1995 to 18 January 2021) according to the PRISMA guidelines. Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N >= 50; non-RCTs: N >= 100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. In total, 61/536 records were eligible (18 RCTs and 39 non-RCTs comprising 13,188 patients), in which 57 factors were reported. Ten factors qualified BM data for meta-analysis: Limited stage disease (LD) (HR = 0.34, 95% CI: 0.17-0.67; P = 0.002) and older age (>= 65) (HR = 0.70, 95% CI: 0.54-0.92; P = 0.01) were associated with less BM; A higher T stage (>= T3) (HR = 1.72, 95% CI: 1.16-2.56; P = 0.007) was a significant risk factor for BM. Male sex (HR = 1.24, 95% CI: 0.99-1.54; P = 0.06) tended to be a risk factor, and better PS (0-1) (HR = 0.66, 95% CI: 0.42-1.02; P = 0.06) tended to have less BM. Smoking, thoracic radiotherapy dose were not significant (P > 0.05). PCI significantly decreased BM (P < 0.001), but did not improve OS in ED-SCLC (P = 0.81). A higher PCI dose did not improve OS (P = 0.11). The impact on BM was conflicting between Cox regression data (HR = 0.59, 95% CI: 0.26-1.31; P = 0.20) and competing risk regression data (HR = 0.74, 95% CI: 0.55-0.99; P = 0.04). Compared to M0-M1a, M1b was a risk factor for OS (P = 0.01) in ED-SCLC, but not for BM (P = 0.19). As regular brain imaging is rarely performed, high-quality data is lacking. Other factors such as N-stage and blood biomarkers had no qualified data to perform meta-analysis. In conclusion, younger age, higher T stage, and ED are risk factors for BM, suggesting that PCI should be especially discussed in such cases. Individual patient data (IPD) meta-analysis and well-designed RCTs are needed to better identify more risk factors and further confirm our findings.
引用
收藏
页数:41
相关论文
共 50 条
  • [31] Risk Factors for Survival after Lung Metastasectomy in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
    Gonzalez, Michel
    Poncet, Antoine
    Combescure, Christophe
    Robert, John
    Ris, Hans Beat
    Gervaz, Pascal
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (02) : 572 - 579
  • [32] Risk Factors for Survival after Lung Metastasectomy in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
    Michel Gonzalez
    Antoine Poncet
    Christophe Combescure
    John Robert
    Hans Beat Ris
    Pascal Gervaz
    Annals of Surgical Oncology, 2013, 20 : 572 - 579
  • [33] Prevalence and risk factors of sleep disturbances among patients with lung cancer: systematic review and meta-analysis
    Hu, Ying
    Xiao, Lily Dongxia
    Tang, Caiyun
    Cao, Wenhui
    Wang, Yao
    SUPPORTIVE CARE IN CANCER, 2024, 32 (09)
  • [34] Systematic review and meta-analysis of risk factors for survival after lung metastasectomy in colorectal cancer patients
    Gonzalez, M.
    Poncet, A.
    Combescure, C.
    Robert, J.
    Ris, H. -B.
    Gervaz, P.
    BRITISH JOURNAL OF SURGERY, 2012, 99 : 22 - 22
  • [35] Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
    Horita, Nobuyuki
    Yamamoto, Masaki
    Sato, Takashi
    Tsukahara, Toshinori
    Nagakura, Hideyuki
    Tashiro, Ken
    Shibata, Yuji
    Watanabe, Hiroki
    Nagai, Kenjiro
    Nakashima, Kentaro
    Ushio, Ryota
    Ikeda, Misako
    Kobayashi, Nobuaki
    Shinkai, Masaharu
    Kudo, Makoto
    Kaneko, Takeshi
    SCIENTIFIC REPORTS, 2016, 6
  • [36] Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients
    Horita, Nobuyuki
    Yamamoto, Masaki
    Sato, Takashi
    Tsukahara, Toshinori
    Nagakura, Hideyuki
    Tashiro, Ken
    Shibata, Yuji
    Watanabe, Hiroki
    Nagai, Kenjiro
    Inoue, Miyo
    Nakashima, Kentaro
    Ushio, Ryota
    Shinkai, Masaharu
    Kudo, Makoto
    Kaneko, Takeshi
    SCIENTIFIC REPORTS, 2015, 5
  • [37] Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
    Nobuyuki Horita
    Masaki Yamamoto
    Takashi Sato
    Toshinori Tsukahara
    Hideyuki Nagakura
    Ken Tashiro
    Yuji Shibata
    Hiroki Watanabe
    Kenjiro Nagai
    Kentaro Nakashima
    Ryota Ushio
    Misako Ikeda
    Nobuaki Kobayashi
    Masaharu Shinkai
    Makoto Kudo
    Takeshi Kaneko
    Scientific Reports, 6
  • [38] Amrubicin For Relapsed Small-Cell Lung Cancer: A Systematic Review And Meta-Analysis Of 803 Patients
    Nakashima, K.
    Horita, N.
    Narita, A.
    Ikeda, M.
    Ushio, R.
    Watanabe, H.
    Nagai, K.
    Shibata, Y.
    Tashiro, K.
    Nagakura, H.
    Tsukahara, T.
    Yamamoto, M.
    Sato, T.
    Kaneko, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [39] Chinese herbal medicine for small cell lung cancer patients A protocol for a systematic review and meta-analysis
    Mi, Xue
    Zhang, Xiwen
    He, Shulin
    Zhang, Zhenhua
    Qi, Runzhi
    Jiang, Juling
    Chen, Shuntai
    Zheng, Honggang
    Hua, Baojin
    MEDICINE, 2020, 99 (52)
  • [40] Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients
    Nobuyuki Horita
    Masaki Yamamoto
    Takashi Sato
    Toshinori Tsukahara
    Hideyuki Nagakura
    Ken Tashiro
    Yuji Shibata
    Hiroki Watanabe
    Kenjiro Nagai
    Miyo Inoue
    Kentaro Nakashima
    Ryota Ushio
    Masaharu Shinkai
    Makoto Kudo
    Takeshi Kaneko
    Scientific Reports, 5